From: Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment
Category | Attribute | Levels | Code |
---|---|---|---|
Motor function | Level of change in motor function | Stable | 1 |
Better | 2 | ||
Breathing function | Level of change in breathing function | Stable | 1 |
Better | 2 | ||
Indication | Drug is approved for | Pediatric and adult patients with SMA | 1 |
Pediatric patients with SMA only (e.g., < 2 years of age) | 2 | ||
Route and frequency of administration | Route and frequency of treatments | Intravenous (IV) infusion—one-time treatment | 1 |
Intrathecal (IT) spinal injection—3–6 times per year | 2 | ||
Oral—daily medication | 3 | ||
Potential harm | Treatments potentially raise severity of harm to patients | Mild risk which may involve minimal or non-invasive medical intervention | 1 |
Moderate risk which may require medical intervention (possibly invasive), but not life threatening | 2 | ||
Serious, or life-threatening risk which may require urgent medical intervention or prolonged hospitalization | 3 |